Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma

被引：28

作者：

Sonpavde, G. ^{[2
]}

Choueiri, T. K. ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02215 USA

[2] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA

来源：

BRITISH JOURNAL OF CANCER | 2012年 / 107卷 / 07期

关键词：

renal cell carcinoma; biomarkers; prognostic; predictive; ENDOTHELIAL GROWTH-FACTOR; SINGLE NUCLEOTIDE POLYMORPHISMS; CARBONIC-ANHYDRASE-IX; INTERFERON-ALPHA; EFFICACY; SUNITINIB; SORAFENIB; CANCER; TEMSIROLIMUS; PREDICTORS;

D O I：

10.1038/bjc.2012.399

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite recent advances, metastatic renal cell carcinoma remains largely an incurable disease. Vascular endothelial growth factor and mammalian target of rapamycin inhibitors have provided improvements in clinical outcomes. High-dose interleukin 2 remains an option for highly selected patients and is associated with durable remissions in a small minority of patients. The toxicity profiles of specific agents and patient characteristics and comorbidities and costs have an important role in the current choice of therapy. Major challenges encountered in developing molecular biomarkers to guide therapy are tumour heterogeneity and standardisation of tissue collection and analysis. Although biomarkers are in their infancy of development, they should be a priority in early preclinical and clinical development in order to guide rational tailored development of emerging agents. British Journal of Cancer (2012) 107, 1009-1016. doi:10.1038/bjc.2012.399 www.bjcancer.com Published online 4 September 2012 (c) 2012 Cancer Research UK

引用

页码：1009 / 1016

页数：8

共 56 条

[1] The Mammalian Target of Rapamycin Pathway Is Widely Activated Without PTEN Deletion in Renal Cell Carcinoma Metastases [J].

Abou Youssif, Tamer ;

Fahmy, Mona Alam ;

Koumakpayi, Ismael Herve ;

Ayala, Fernanda ;

Al Marzooqi, Saeeda ;

Chen, Guangyong ;

Tamboli, Pheroze ;

Squire, Jeremy ;

Tanguay, Simon ;

Sircar, Kanishka .

CANCER, 2011, 117 (02) :290-300

[2]

[Anonymous], J CLIN ONCOL S

[3]

[Anonymous], J CLIN ONCOL

[4]

Armstrong AJ, 2012, J CLIN ONCOL

[5] Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer [J].

Atkins, M ;

Regan, M ;

McDermott, D ;

Mier, J ;

Stanbridge, E ;

Youmans, A ;

Febbo, P ;

Upton, M ;

Lechpammer, M ;

Signoretti, S .

CLINICAL CANCER RESEARCH, 2005, 11 (10) :3714-3721

[6] Modes of resistance to anti-angiogenic therapy [J].

Bergers, Gabriele ;

Hanahan, Douglas .

NATURE REVIEWS CANCER, 2008, 8 (08) :592-603

[7] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[8]

Brannon A Rose, 2010, Genes Cancer, V1, P152

[9]

Chen JL, 2011, J CLIN ONCOL S, V29

[10] Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma [J].

Cho, Daniel ;

Signoretti, Sabina ;

Dabora, Sandra ;

Regan, Meredith ;

Seeley, Apryle ;

Mariotti, Mauro ;

Youmans, Amanda ;

Polivy, Adam ;

Mandato, Lucy ;

McDermott, David ;

Stanbridge, Eric ;

Atkins, Michael .

CLINICAL GENITOURINARY CANCER, 2007, 5 (06) :379-385

← 1 2 3 4 5 6 →